Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives

1. A compound of the formula (I)

wherein

R 1 is H, OH or NH 2 ;

R 3 is H, halogen, CN, (C 1 -C 6 )alkyl, OH, NH 2 , or NHR′;

R 4 is H, halogen, hydroxy, CN, (C 1 -C 6 )alkyl, R′, or (C 1 -C 6 )alkylene-R′;

R 5 is H, halogen, CN, (C 1 -C 6 )alkyl, or R′;

R 7 is H, halogen, CN, (C 1 -C 6 )alkyl, O—(C 1 -C 6 )alkyl, R′, or SO 2 —NH 2 ;

R 8 is H, halogen or (C 1 -C 6 )alkyl;

R 6 is one (C 1 -C 4 )alkylene bound to the cycloalkyl ring, in which the (C 1 -C 4 )alkylene forms a second bond to a different carbon atom of the cycloalkyl ring to form a bicyclic ring system, wherein in the bicyclic ring system one or two carbon atoms are replaced by a group independently selected from O, N—R 13 , S, SO or SO 2 ;

or, if m and s are 2, m is 3 and s is 1, or m is 4 and s is 0,

R 6 is CH 2 —CH—(CH 2 ) 2 which is bound with one CH 2 to the cycloalkyl ring and the two other CH 2 are bound to different carbon atoms of the cycloalkyl ring,

and, if m is 3 and s is 3,

R 6 are two methylene groups bound to different carbon atoms of the cycloalkyl ring, wherein the methylene groups or the CH 2 —CH—(CH 2 ) 2 group are bound to carbon atoms of the cycloalkyl ring and form an adamantane system of the formula

wherein L can be bound to any secondary or tertiary carbon atom,

or R 6 together with R 11 and the N atom form a (C 3 -C 8 )heterocycloalkyl which is connected as a spirocyclic ring system to the cycloalkyl residue to form a residue of the formula

wherein the bicyclic ring system or adamantane system or the (C 3 -C 8 )heterocycloalkyl containing ring system is unsubstituted or optionally substituted by R 9 ;

R 9 is

R′,

OH,

halogen,

(C 1 -C 6 )alkyl,

O—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-R′,

(C 2 -C 6 )alkenyl,

(C 2 -C 6 )alkynyl,

(C 1 -C 6 )alkylene-O—R′,

(C 1 -C 6 )alkylene-CH[R′] 2 ,

(C 1 -C 6 )alkylene-C(O)—R′,

(C 1 -C 6 )alkylene-C(O)NH 2 ,

(C 1 -C 6 )alkylene-C(O)NH—R′,

(C 1 -C 6 )alkylene-C(O)NH—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-C(O)N[(C 1 -C 6 )alkyl] 2 ,

(C 1 -C 6 )alkylene-C(O)N[R′] 2 ;

(C 1 -C 6 )alkylene-C(O)O—(C 1 -C 6 )alkyl,

COOH,

C(O)O—(C 1 -C 6 )alkyl,

C(O)OR′

C(O)(C 1 -C 6 )alkyl,

C(O)R′,

CONH 2 ,

C(O)—NH—(C 2 -C 6 )alkenyl,

C(O)—NH—(C 2 -C 6 )alkynyl,

C(O)NH—(C 1 -C 6 )alkyl,

C(O)NHR′,

C(O)—NH(C 1 -C 6 )alkylene-R′,

C(O)N[(C 1 -C 6 )alkyl]R′,

C(O)N[(C 1 -C 6 )alkyl] 2 ,

C(O)—(C 1 -C 6 )alkylene-R′, or

C(O)O(C 1 -C 6 )alkylene-R′;

R 11 and R 12 are independently of each other

H,

R′,

(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-R′,

(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-O—R′,

(C 1 -C 6 )alkylene-CH[R′] 2 ,

(C 1 -C 6 )alkylene-C(O)—R′,

(C 1 -C 6 )alkylene-C(O)NH 2 ,

(C 1 -C 6 )alkylene-C(O)NH—R′,

(C 1 -C 6 )alkylene-C(O)NH—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-C(O)N[(C 1 -C 6 )alkyl] 2 ,

(C 1 -C 6 )alkylene-C(O)N[R′] 2 ,

(C 1 -C 6 )alkylene-C(O)O—(C 1 -C 6 )alkyl,

C(O)O—(C 1 -C 6 )alkyl,

C(O)OR′,

C(O)(C 1 -C 6 )alkyl,

C(O)R′,

C(O)NH—(C 1 -C 6 )alkyl,

C(O)NHR′,

C(O)N[(C 1 -C 6 )alkyl]R′,

C(O)N[(C 1 -C 6 )alkyl] 2 ,

C(O)—(C 1 -C 6 )alkylene-R′,

C(O)O(C 1 -C 6 )alkylene-R′, or

R 11 and R 12 , together with the N-atom to which they are attached, form a (C 3 -C 8 ) heterocycloalkyl;

R 13 is H or (C 1 -C 6 )alkyl;

n is 0, 1, 2, 3 or 4;

m is 1, 2, 3 or 4;

s is 0, 1, 2, or 3;

L is O(CH 2 ) p , S(CH 2 ) p , S(O)(CH 2 ) p , SO 2 (CH 2 ) p , NH(CH 2 ) p , N(C 1 -C 6 )alkyl-(CH 2 ) p , N(C 3 -C 6 )cycloalkyl-(CH 2 ) p ; or N[(C 1 -C 3 )alkylene-R′]—(CH 2 ) p ;

p is 0, 1, 2, 3 or 4;

R′ is

(C 3 -C 8 )cycloalkyl,

(C 5 -C 10 )heteroaryl,

(C 3 -C 8 )heterocycloalkyl,

(C 6 -C 10 )aryl;

wherein in residues R 3 to R 13 alkyl or alkylene is unsubstituted or optionally substituted one or more times by OH, OCH 3 , C(O)OH, C(O)OCH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , C(O)NH 2 , C(O)NHCH 3 or C(O)N(CH 3 ) 2 ;

wherein in residues R 3 to R 13 cycloalkyl or heterocycloalkyl is unsubstituted or optionally substituted one or more times by (C 1 -C 6 )alkyl, halogen, OH, OCH 3 , C(O)OH, C(O)OCH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , C(O)NH 2 , C(O)NHCH 3 or C(O)N(CH 3 ) 2 ;

wherein in residues R 3 to R 13 alkyl or alkylene is unsubstituted or optionally substituted one or more times by halogen;

wherein in residues R 3 to R 13 (C 6 -C 10 )aryl and (C 5 -C 10 )heteroaryl are unsubstituted or optionally substituted one or more times by a group independently selected from halogen, OH, NO 2 , N 3 , CN, C(O)—(C 1 -C 6 )alkyl, C(O)—(C 6 -C 10 )aryl, C(O)OH, C(O)O(C 1 -C 6 )alkyl, C(O)NH 2 , C(O)NH(C 1 -C 6 )alkyl, C(O)N[(C 1 -C 6 )alkyl] 2 , (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-NH(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-N[(C 1 -C 6 )alkyl] 2 , (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, O—(C 1 -C 6 )alkyl, O—C(O)—(C 1 -C 6 )alkyl, PO 3 H 2 , SO 3 H, SO 2 —NH 2 , SO 2 NH(C 1 -C 6 )alkyl, SO 2 N[(C 1 -C 6 )alkyl] 2 , S—(C 1 -C 6 )alkyl; SO—(C 1 -C 6 )alkyl, SO 2 —(C 1 -C 6 )alkyl, SO 2 —N═CH—N[(C 1 -C 6 )alkyl] 2 , SF 5 , C(NH)(NH 2 ), NH 2 , NH—(C 1 -C 6 )alkyl, N[(C 1 -C 6 )alkyl] 2 , NH—C(O)—(C 1 -C 6 )alkyl, NH—C(O)O—(C 1 -C 6 )alkyl, NH—SO 2 —(C 1 -C 6 )alkyl, NH—SO 2 —(C 6 -C 10 )aryl, NH—SO 2 —(C 5 -C 10 )heteroaryl, NH—SO 2 —(C 3 -C 8 )heterocycloalkyl, N(C 1 -C 6 )alkyl-C(O)—(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl-C(O)O—(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl-C(O)—NH—(C 1 -C 6 )alkyl], (C 6 -C 10 )aryl, (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, O—(C 6 -C 10 )aryl, O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, (C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, (C 1 -C 6 )alkylene-(C 5 -C 10 )heteroaryl, (C 1 -C 6 )alkylene-(C 3 -C 8 )heterocycloalkyl, O—(C 1 -C 6 )alkylene-(C 5 -C 10 )heteroaryl, O—(C 1 -C 6 )alkylene-(C 3 -C 8 )heterocycloalkyl,

wherein said (C 6 -C 10 )aryl, (C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, or (C 3 -C 8 )cycloalkyl may be substituted one to three times by a group independently selected from halogen, OH, NO 2 , CN, O—(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl, NH 2 , NH(C 1 -C 6 )alkyl, N[(C 1 -C 6 )alkyl] 2 , SO 2 CH 3 , C(O)OH, C(O)O—(C 1 -C 6 )alkyl, C(O)NH 2 , (C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-O—(C 6 -C 10 )aryl, or O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl;

or wherein (C 6 -C 10 )aryl is vicinally substituted by a O—(C 1 -C 4 )alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to;

and wherein aryl substituents of (C 6 -C 10 )aryl, (C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl and (C 3 -C 8 )cycloalkyl groups may not be further substituted by an aryl, heteroaryl, heterocycloalkyl, or cycloalkyl containing group;

their stereoisomeric and/or tautomeric forms or a pharmaceutically acceptable salt.

2. A compound of formula (I) according to claim 1 , wherein R 1 is H and is characterized by the formula (II)

3. A compound of formula (I) according to claim 1 , wherein R 1 is OH and is characterized by the formula (IIIa)

or by the formula (Mb)

4. A compound according to claim 1 , wherein R 1 is NH 2 .

5. A compound according to one of claims 1 to 4 , wherein R 3 is H, halogen, (C 1 -C 6 )alkyl, or NHR′, wherein (C 1 -C 6 )alkyl and R′ are unsubstituted or substituted.

6. A compound according to one of claims 1 to 4 , wherein R 3 is H.

7. A compound according to one of claims 1 to 4 , wherein R 4 is H, halogen, (C 1 -C 6 )alkyl or (C 1 -C 2 )-phenyl, wherein (C 1 -C 6 )alkyl or phenyl are unsubstituted or substituted.

8. A compound according to one of claims 1 to 4 , wherein R 4 is H.

9. A compound according to one of claims 1 to 4 , wherein R 5 is H, halogen, (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, or (C 5 -C 10 )heteroaryl, wherein (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, or (C 5 -C 10 )heteroaryl are unsubstituted or substituted.

10. A compound according to one of claims 1 to 4 , wherein R 5 is H.

11. A compound according to one of claims 1 to 4 , wherein R 7 is H, halogen, (C 1 -C 6 )alkyl, O—(C 1 -C 6 )alkyl, or R′, wherein (C 1 -C 6 )alkyl or R′ are unsubstituted or substituted.

12. A compound according to one of claims 1 to 4 , wherein R 7 is chloro.

13. A compound according to one of claims 1 to 4 , wherein R 8 is H.

14. A compound according to one of claims 1 to 4 , wherein R 9 is

R′,

OH,

halogen,

(C 1 -C 6 )alkyl,

(C 1 -C 8 )heteroalkyl,

(C 1 -C 6 )alkylene-R′,

(C 2 -C 6 )alkenyl,

(C 1 -C 6 )alkylene-C(O)NH—R′,

(C 1 -C 6 )alkylene-C(O)NH—(C 1 -C 6 )alkyl,

COOH,

CONH 2 ,

C(O)NH—(C 1 -C 6 )alkyl,

C(O)NHR′,

C(O)—NH—(C 1 -C 6 )alkynyl,

C(O)—NH(C 1 -C 6 )alkylene-R′, or

C(O)N[(C 1 -C 6 )alkyl] 2 ;

wherein (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene or R′ are unsubstituted or substituted.

15. A compound according to one of claims 1 to 4 , wherein R 9 is OH, halogen, (C 1 -C 6 )alkyl, R′, (C 1 -C 6 )alkylene-R′, (C 2 -C 6 )alkenyl, COOH, CONH 2 , C(O)NH—(C 1 -C 6 )alkyl, C(O)NHR', or C(O)N[(C 1 -C 6 )alkyl] 2 , wherein alkyl, alkylene and R′ are unsubstituted or substituted.

16. A compound according to one of claims 1 to 4 , wherein R 9 is OH, halogen, (C 1 -C 6 )alkyl, COOH, CONH 2 , O—CH 3 , phenyl, (C 1 -C 2 )alkylene-phenyl, (C 3 -C 8 )cycloalkyl, wherein alkyl, phenyl or (C 3 -C 8 )cycloalkyl is unsubstituted or substituted.

17. A compound according to one of claims 1 to 4 , wherein R 9 is allyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethylene, isopropyloxymethylene, tetrahydrofuranyl, tetrahydropyranyl, phenyl or benzyl.

18. A compound according to one of claims 1 to 4 , wherein R 11 and R 12 are independently of each other

H,

(C 1 -C 6 )alkyl,

(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 5 -C 10 )heteroaryl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )heterocycloalkyl,

C 1 -C 4 )alkylene-(C 6 -C 10 )aryl,

(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl,

C(O)NH—(C 1 -C 6 )alkyl, or

R 11 and R 12 , together with the N-atom to which they are attached, form a (C 3 -C 8 ) heterocycloalkyl group;

wherein (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene, C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, or (C 6 -C 10 )aryl are unsubstituted or substituted.

19. A compound according to any of claims 1 to 4 , wherein

R 11 is H or (C 1 -C 6 )alkyl; and

R 12 is

H,

(C 1 -C 6 )alkyl,

(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 5 -C 10 )heteroaryl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )heterocycloalkyl,

(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl, or

(C 1 -C 4 )alkylene-O—(C 1 -C 6 )alkyl,

wherein (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene, (C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, or (C 6 -C 10 )aryl are unsubstituted or substituted.

20. A compound according to any of claims 1 to 4 , wherein

R 11 is H and

R 12 is H, (C 1 -C 6 )alkyl or (C 3 -C 8 )cycloalkyl,

wherein (C 1 -C 6 )alkyl or (C 3 -C 8 )cycloalkyl are unsubstituted or substituted.

21. A compound according to any of claims 1 to 4 , wherein R 11 and R 12 are H.

22. A compound according to one of claims 1 to 4 , wherein the bicyclus formed with R 6 is selected from the group

which is unsubstituted or optionally substituted by R 9 .

23. A compound according to one of claims 1 to 4 , wherein the adamantane formed with R 6 is selected from

which is unsubstituted or optionally substituted by residues R 9 .

24. A compound according to one of claims 1 to 4 , wherein R 6 together with R 11 and the N atom form a (C 3 -C 8 )heterocycloalkyl which is connected as a spirocyclic system to the cycloalkyl residue to give a residue of the formula

wherein the (C 3 -C 8 )heterocycloalkyl containing ring system is unsubstituted or optionally substituted by R 9 .

25. A compound according to one of claims 1 to 4 , wherein m is 2 and s is 2.

26. A compound according to one of claims 1 to 4 wherein m is 3 and s is 1.

27. A compound according to one of claims 1 to 4 , wherein n is 0.

28. A compound according to one of claims 1 to 4 , wherein L is S(CH 2 ) p , S(O)(CH 2 ) p , or SO 2 (CH 2 ) p .

29. A compound according to one of claims 1 to 4 , wherein L is NH(CH 2 ) p or N(C 1 -C 6 )alkyl)-(CH 2 ) p .

30. A compound according to one of claims 1 to 4 , wherein L is O(CH 2 ) p .

31. A compound according to one of claims 1 to 4 , wherein p is 0.

32. A compound according to claim 1 selected from the group consisting of

6-(4-Amino-adamantan-1-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-(4-Allyl-4-amino-adamantan-1-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-(4-Amino-4-propyl-adamantan-1-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-(4-Amino-4-methyl-adamantan-1-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-(4-Amino-4-phenyl-adamantan-1-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-(4-Amino-4-cyclopropyl-adamantan-1-yloxy)-7-chloro-2,4-isoquinolin-1-one,

6-(4-Benzylamino-adamantan-1-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-(3-Amino-adamantan-1-yloxy)-7-chloro-2,4-isoquinolin-1-one,

6-(5-Amino-adamantan-2-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-(5-Amino-adamantan-2-yloxy)-7-methyl-2H-isoquinolin-1-one,

6-{[(7-amino-3-oxabicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one,

6-{[(7-amino-3-thiabicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one,

6-{[(7-amino-3-(dioxo-thia)bicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one, 3,3-dioxide, or

6-(1-Aza-spino[4.5]dec-8-yloxy)-7-chloro-2H-isoquinolin-1-one,

their stereoisomeric and/or tautomeric forms or a pharmaceutically acceptable salt.

33. A compound according to claim 1 selected from the group consisting of

cis-6-(5-Amino-adamantan-2-yloxy)-7-chloro-2H-isoquinolin-1-one,

trans-6-(5-Amino-adamantan-2-yloxy)-7-chloro-2H-isoquinolin-1-one,

6-{[(7-Endo,9-anti)-7-amino-3-oxabicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one,

6-{[(7-endo,9-syn)-7-amino-3-oxabicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one,

6-{[(7-Endo,9-anti)-7-amino-3-thiabicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one,

6-{[(7-endo,9-syn)-7-amino-3-thiabicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one, and

6-{[(7-Endo,9-anti)-7-amino-3-(dioxo-thia)bicyclo[3.3.1]non-9-yl]oxy}-7-chloroisoquinolin-1(2H)-one, 3,3-dioxide,

their stereoisomeric and/or tautomeric forms or a pharmaceutically acceptable salt.

34. A compound of formula (I) and/or its pharmaceutically acceptable salt according to one of claims 1 to 4 for use as a medicament.

35. A method for the treatment and/or prevention of hypertension, pulmonary hypertension, ocular hypertension, retinopathy, glaucoma, peripheral circulatory disorder, peripheral arterial occlusive disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral vasospasm, cerebral ischemia, pain, neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy, infection of digestive tracts with bacteria, sepsis or cancer development and progression by administering a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need of said treatment.

36. A method for the treatment and/or prevention of hypertension, pulmonary hypertension, fibroid liver, liver failure, nephropathy, renal failure, chronic obstructive pulmonary disease (COPD), cerebral vasospasm, pain, spinal cord injury, erectile dysfunction, blood vessel restenosis, or cancer development and progression by administering a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need of said treatment.

37. A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and/or a pharmacologically acceptable salt thereof according to one of claims 1 to 4 , pharmaceutically tolerated excipients and carriers and, where appropriate, further additives and/or other active ingredients.